In one paragraphArticle in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Mingfei YanDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-2054-5986 Michelly K Sampaio De MeloLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-5447-7440 Nathaniel AleynickDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-3726-1285 Alexander ChanDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5884-8424 Ozgur Can ErenDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-9889-2702 Katherine LopezDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Alexa CohenDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Mikhail RoshalDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Megan S LimDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-0415-2867 Leonardo BoiocchiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5188-6217 Ahmet DoganDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6576-5256 Yanming ZhangDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Elaine S JaffeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Rebecca L KingDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
Wenbin XiaoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-8586-8500 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MThe Memorial Sloan Kettering Cancer Center SPORE in LeukemiaP50CA254838 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eytan Stein · 2021 to 2026
$16.8MAssessing lineage infidelity, oncogenic cooperativity and dependency in RUNX1-mutant acute myeloid leukemiaK08CA267058 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI XIAO, WENBIN · 2022 to 2025
$1.1MDeciphering pathogenesis and therapeutic vulnerabilities in germline RUNX1 mutated AMLR37CA301130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Wenbin Xiao · 2025 to 2026
$991kNCI NIH HHS K08 CA267058NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA254838NCI NIH HHS R37 CA301130
6 · The paper itselfAbstract
Richter transformation of Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) into classic Hodgkin lymphoma (CHL-RT) is rare and remains incompletely understood. Two histologic subtypes are recognized: type 1 (CLL/SLL with scattered Hodgkin/Reed-Sternberg (HRS) cells) and type 2 (HRS cells within a polymorphous inflammatory background). In this multi-institutional study of 77 patients with CHL-RT (27 type 1 and 50 type 2), we characterized immune evasion markers,
Indexed as
classic Hodgkin lymphomaCLL/SLLgenetic riskimmune evasionmutationsPD-L1/PD-L2Richter’s transformation
Identifiers
PMID42238415
PMCPMC13228784
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390